BusinessElite Pharmaceuticals Files ANDA for Oxycodone Hydrochloride Extended ReleaseBy Nasdaq OMXSep 20, 2017, 12:38 PM UTC
BusinessElite Pharmaceuticals to Present ELI-200 (SequestOx™) Data at PAINWeek 2017 National ConferenceBy Nasdaq OMXAug 30, 2017, 12:01 PM UTC
BusinessElite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2018 Ended June 30, 2017 and Provides Conference Call InformationBy Nasdaq OMXAug 9, 2017, 8:39 PM UTC
BusinessElite Pharmaceuticals, Inc. to Host Conference Call to Discuss First Quarter Financial Results on August 10, 2017By Nasdaq OMXAug 8, 2017, 12:01 PM UTC
BusinessElite Announces Co-Development of Four Additional Products with SunGen PharmaBy Nasdaq OMXJul 28, 2017, 12:00 PM UTC
BusinessElite Announces New Development and License Agreement with SunGen Pharma LLCBy Nasdaq OMXJul 12, 2017, 12:32 PM UTC
BusinessElite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx™By Nasdaq OMXJul 7, 2017, 4:48 PM UTC
BusinessElite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2017 and Provides Conference Call InformationBy Nasdaq OMXJun 14, 2017, 8:59 PM UTC
